Competitive blockade of CD300ld by its extracellular domain (ECD) inhibits the growth of established tumour in a way similar to CD300ld KO, and exhibits a significant anti‐tumour synergy effect with anti‐PD1, indicating that CD300ld can serve as a therapeutic target. This evidence concerns the gene CD300LD and neoplasm.